Pace Logo

Life Sciences

ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Pace ® is happy to share news from our client, ReveraGen BioPharma Inc., on a significant accomplishment! ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy. Pace® Ann Arbor (legacy Velesco Pharmaceutical Services) contributed significantly to this success. Velesco Pharma (now Pace®) performed the drug product clinical formulation development and all drug […]

ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy Read More »

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of therapeutic classes. Minneapolis, MN, September 1, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace®, ascience and technology company, announced today that it has acquired Biopharma

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation Read More »

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract Read More »

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts

Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences, a division of Pace® Science and Technology Company, is pleased to announce that it has received a Bronze Award for its current state of sustainability. This award signifies that Pace® is in the top 50%

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts Read More »

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf

Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar presented by Dave Barnes, Ph.D., Vice President of Scientific Affairs for Pace® Life Sciences. To watch it live, tune in on Thursday, April 14 at 11 AM EDT. REGISTER HERE REGISTER HERE This presentation focuses

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf Read More »

Pace® Life Sciences Acquires Velesco Pharmaceutical Services

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development

Pace® Life Sciences Acquires Velesco Pharmaceutical Services Read More »